Alleyba says................
...........that this is the case for SCRC
1.ScripsAmerica’s Pediatric “RapiMed” will compete with other children’s analgesic products, such as Johnson & Johnson’s Children’s Tylenol Suspension Liquid and Children’s Tylenol Meltaways, Novartis’ Triaminic Fever Reducer Pain Reliever, and Perrigo’s Junior Strength Non-Aspirin Suspension Liquids & Drugs. According to Euromonitor International’s research, J&J’s Children’s Tylenol sales represented 23% of global and 76% of U.S. retail value sales in child-specific analgesics. Global sales were valued at $695 million in 2012.
J&J cannot manufacture or distribute the drug until the last quarter of 2014. We have the competitive advantage to dominate Global sales;
2.The acquisition of PIMD. which according to its web site did $1,000,000-%5,000,000 on its own will add revenues to SCRC bottom line and helps increase our profit margin through packaging and distribution. That is not mentioning the strtegic location of the company from a shipping point of view being less than a mile from the airport and 10 miles from Port Of Everglades;
3. The entry into the China market will be the bonanza to this company as they capture a large portion of market share with Repimeds worth millions of dollars;
4.Once China is secured or simultaneously with China I believe the CEO, in my opinion, would be smart to expand into other countries aa well;
5. Per the agreement with Seacoast and GEM SCRC is now positioned to produce and distribute Rapimeds globally and domestically;
6. The TN. cooperative selling is a success and the numbers have increases every month and it appears to me that at a MINIMUM this is worth $1,500,000 a year to SCRC with the potential to expand this market through other innovative ways which IMO CEO working on.
7. The 8-K stated that SCRC to obtain license to distribute "controlled dangerous substances". Here come the generic pain killers and sleeping pills more millions of dollars;
8. The masterful execution of financial agreement with GEM and the partner group potentially enhances the SCRC brand in the 65 countries GEM haa a presence in and enabled company to obtain the financing for acquisition, distribution, packaging and promotion of SCRC. Why would GEM take an interest in SCRC if they did not like the company or concept;
9. CEO has done masterful job in accomplishing the above without dilution of company stock and values shareholders who have stood by him and will do everything he can to maximize shareholder value;
10, The PIMD acquisition enables company and opens door to get involved in the revenue stream of medical devices and not just Rapimeds and other drugs.
11. DOD contract runs another couple of years adding more revenue
I can probably go on with this list but the point is the CEO is developing several revenue streams which will not only grow but will continue each anf every month. I acknowledged that in order to get the company off the ground he had to make certain deals that may not have been as favorable as he would have liked so there was some paper given. He had no choice, but as he has leveled the playing field out he has taken out that paper and what you are now seeing is some of that paper being absorbed by the people who realize the potential of this company and understand that there has been no real dilution in months....so once this selling is done there will nothing to stop this stock from marching upwards and establishing new highs. In 18-24 months based on what CEO is doing I can see this stock trading at $2-$4 dollars and I think that is conservatively speaking
...........that this is the case for SCRC
1.ScripsAmerica’s Pediatric “RapiMed” will compete with other children’s analgesic products, such as Johnson & Johnson’s Children’s Tylenol Suspension Liquid and Children’s Tylenol Meltaways, Novartis’ Triaminic Fever Reducer Pain Reliever, and Perrigo’s Junior Strength Non-Aspirin Suspension Liquids & Drugs. According to Euromonitor International’s research, J&J’s Children’s Tylenol sales represented 23% of global and 76% of U.S. retail value sales in child-specific analgesics. Global sales were valued at $695 million in 2012.
J&J cannot manufacture or distribute the drug until the last quarter of 2014. We have the competitive advantage to dominate Global sales;
2.The acquisition of PIMD. which according to its web site did $1,000,000-%5,000,000 on its own will add revenues to SCRC bottom line and helps increase our profit margin through packaging and distribution. That is not mentioning the strtegic location of the company from a shipping point of view being less than a mile from the airport and 10 miles from Port Of Everglades;
3. The entry into the China market will be the bonanza to this company as they capture a large portion of market share with Repimeds worth millions of dollars;
4.Once China is secured or simultaneously with China I believe the CEO, in my opinion, would be smart to expand into other countries aa well;
5. Per the agreement with Seacoast and GEM SCRC is now positioned to produce and distribute Rapimeds globally and domestically;
6. The TN. cooperative selling is a success and the numbers have increases every month and it appears to me that at a MINIMUM this is worth $1,500,000 a year to SCRC with the potential to expand this market through other innovative ways which IMO CEO working on.
7. The 8-K stated that SCRC to obtain license to distribute "controlled dangerous substances". Here come the generic pain killers and sleeping pills more millions of dollars;
8. The masterful execution of financial agreement with GEM and the partner group potentially enhances the SCRC brand in the 65 countries GEM haa a presence in and enabled company to obtain the financing for acquisition, distribution, packaging and promotion of SCRC. Why would GEM take an interest in SCRC if they did not like the company or concept;
9. CEO has done masterful job in accomplishing the above without dilution of company stock and values shareholders who have stood by him and will do everything he can to maximize shareholder value;
10, The PIMD acquisition enables company and opens door to get involved in the revenue stream of medical devices and not just Rapimeds and other drugs.
11. DOD contract runs another couple of years adding more revenue
I can probably go on with this list but the point is the CEO is developing several revenue streams which will not only grow but will continue each anf every month. I acknowledged that in order to get the company off the ground he had to make certain deals that may not have been as favorable as he would have liked so there was some paper given. He had no choice, but as he has leveled the playing field out he has taken out that paper and what you are now seeing is some of that paper being absorbed by the people who realize the potential of this company and understand that there has been no real dilution in months....so once this selling is done there will nothing to stop this stock from marching upwards and establishing new highs. In 18-24 months based on what CEO is doing I can see this stock trading at $2-$4 dollars and I think that is conservatively speaking
